An unprofitable biotech that pioneered a relatively new kind of cancer therapy has caught the
The attention of the top drugmakers in the world
On the lookout for the next big opportunity within one of the most lucrative markets in the industry.
Seagen Inc. offers three novel cancer agents, known as
antibody drug conjugates
, or ADCs—that work like a guided missile attacking tumors with toxins. Although the company's products generate around $2 billion in yearly sales and the company operates at a loss, it has a market valuation of roughly $30 billion.